Pharmacokinetics of oseltamivir among pregnant and nonpregnant women

Richard H. Beigi, Kelong Han, Raman Venkataramanan, Gary Hankins, Shannon Clark, Mary F. Hebert, Thomas Easterling, Anne Zajicek, Zhaoxia Ren, Donald R. Mattison, Steve N. Caritis

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of pregnancy, including increased renal filtration and secretion, may increase the clearance of oseltamivir carboxylate. Sixteen pregnant women taking oseltamivir for prophylaxis or treatment of suspected/proven influenza infection were enrolled. Twenty-three nonpregnant reproductive-age females served as the control group. The primary PK endpoint was area under the plasma concentration time curve for oseltamivir carboxylate. Pregnancy did not alter the PK parameters of the parent compound, oseltamivir. However, for oseltamivir carboxylate the area under the plasma concentration time curve was significantly lower (P = .007) and the apparent clearance significantly higher (P = .006) in pregnant women compared with nonpregnant women. Pregnancy produces lower systemic levels of oseltamivir carboxylate. Increasing the dose and/or dosing frequency of oseltamivir during pregnancy may be necessary to achieve comparable exposure in pregnant and nonpregnant women.

Original languageEnglish
JournalAmerican Journal of Obstetrics and Gynecology
Volume204
Issue number6 SUPPL.
DOIs
StatePublished - Jun 2011

Fingerprint

Oseltamivir
Pregnant Women
Pharmacokinetics
Pregnancy
Human Influenza
oseltamivir carboxylate
Kidney
Control Groups
Infection

Keywords

  • influenza
  • oseltamivir
  • pregnancy
  • treatment

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Beigi, R. H., Han, K., Venkataramanan, R., Hankins, G., Clark, S., Hebert, M. F., ... Caritis, S. N. (2011). Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. American Journal of Obstetrics and Gynecology, 204(6 SUPPL.). https://doi.org/10.1016/j.ajog.2011.03.002

Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. / Beigi, Richard H.; Han, Kelong; Venkataramanan, Raman; Hankins, Gary; Clark, Shannon; Hebert, Mary F.; Easterling, Thomas; Zajicek, Anne; Ren, Zhaoxia; Mattison, Donald R.; Caritis, Steve N.

In: American Journal of Obstetrics and Gynecology, Vol. 204, No. 6 SUPPL., 06.2011.

Research output: Contribution to journalArticle

Beigi, RH, Han, K, Venkataramanan, R, Hankins, G, Clark, S, Hebert, MF, Easterling, T, Zajicek, A, Ren, Z, Mattison, DR & Caritis, SN 2011, 'Pharmacokinetics of oseltamivir among pregnant and nonpregnant women', American Journal of Obstetrics and Gynecology, vol. 204, no. 6 SUPPL.. https://doi.org/10.1016/j.ajog.2011.03.002
Beigi, Richard H. ; Han, Kelong ; Venkataramanan, Raman ; Hankins, Gary ; Clark, Shannon ; Hebert, Mary F. ; Easterling, Thomas ; Zajicek, Anne ; Ren, Zhaoxia ; Mattison, Donald R. ; Caritis, Steve N. / Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. In: American Journal of Obstetrics and Gynecology. 2011 ; Vol. 204, No. 6 SUPPL.
@article{adecd4df4bc148cda8da97ca4eb62e81,
title = "Pharmacokinetics of oseltamivir among pregnant and nonpregnant women",
abstract = "We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of pregnancy, including increased renal filtration and secretion, may increase the clearance of oseltamivir carboxylate. Sixteen pregnant women taking oseltamivir for prophylaxis or treatment of suspected/proven influenza infection were enrolled. Twenty-three nonpregnant reproductive-age females served as the control group. The primary PK endpoint was area under the plasma concentration time curve for oseltamivir carboxylate. Pregnancy did not alter the PK parameters of the parent compound, oseltamivir. However, for oseltamivir carboxylate the area under the plasma concentration time curve was significantly lower (P = .007) and the apparent clearance significantly higher (P = .006) in pregnant women compared with nonpregnant women. Pregnancy produces lower systemic levels of oseltamivir carboxylate. Increasing the dose and/or dosing frequency of oseltamivir during pregnancy may be necessary to achieve comparable exposure in pregnant and nonpregnant women.",
keywords = "influenza, oseltamivir, pregnancy, treatment",
author = "Beigi, {Richard H.} and Kelong Han and Raman Venkataramanan and Gary Hankins and Shannon Clark and Hebert, {Mary F.} and Thomas Easterling and Anne Zajicek and Zhaoxia Ren and Mattison, {Donald R.} and Caritis, {Steve N.}",
year = "2011",
month = "6",
doi = "10.1016/j.ajog.2011.03.002",
language = "English",
volume = "204",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Pharmacokinetics of oseltamivir among pregnant and nonpregnant women

AU - Beigi, Richard H.

AU - Han, Kelong

AU - Venkataramanan, Raman

AU - Hankins, Gary

AU - Clark, Shannon

AU - Hebert, Mary F.

AU - Easterling, Thomas

AU - Zajicek, Anne

AU - Ren, Zhaoxia

AU - Mattison, Donald R.

AU - Caritis, Steve N.

PY - 2011/6

Y1 - 2011/6

N2 - We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of pregnancy, including increased renal filtration and secretion, may increase the clearance of oseltamivir carboxylate. Sixteen pregnant women taking oseltamivir for prophylaxis or treatment of suspected/proven influenza infection were enrolled. Twenty-three nonpregnant reproductive-age females served as the control group. The primary PK endpoint was area under the plasma concentration time curve for oseltamivir carboxylate. Pregnancy did not alter the PK parameters of the parent compound, oseltamivir. However, for oseltamivir carboxylate the area under the plasma concentration time curve was significantly lower (P = .007) and the apparent clearance significantly higher (P = .006) in pregnant women compared with nonpregnant women. Pregnancy produces lower systemic levels of oseltamivir carboxylate. Increasing the dose and/or dosing frequency of oseltamivir during pregnancy may be necessary to achieve comparable exposure in pregnant and nonpregnant women.

AB - We sought to delineate the pharmacokinetics (PK) of oseltamivir and its active metabolite oseltamivir carboxylate during pregnancy. Physiologic changes of pregnancy, including increased renal filtration and secretion, may increase the clearance of oseltamivir carboxylate. Sixteen pregnant women taking oseltamivir for prophylaxis or treatment of suspected/proven influenza infection were enrolled. Twenty-three nonpregnant reproductive-age females served as the control group. The primary PK endpoint was area under the plasma concentration time curve for oseltamivir carboxylate. Pregnancy did not alter the PK parameters of the parent compound, oseltamivir. However, for oseltamivir carboxylate the area under the plasma concentration time curve was significantly lower (P = .007) and the apparent clearance significantly higher (P = .006) in pregnant women compared with nonpregnant women. Pregnancy produces lower systemic levels of oseltamivir carboxylate. Increasing the dose and/or dosing frequency of oseltamivir during pregnancy may be necessary to achieve comparable exposure in pregnant and nonpregnant women.

KW - influenza

KW - oseltamivir

KW - pregnancy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79957983476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957983476&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2011.03.002

DO - 10.1016/j.ajog.2011.03.002

M3 - Article

C2 - 21492826

AN - SCOPUS:79957983476

VL - 204

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6 SUPPL.

ER -